SRR6013561
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.530
- PROTEIN_SECRETION+0.530
- TNFA_SIGNALING_VIA_NFKB+0.520
- APOPTOSIS+0.430
- INFLAMMATORY_RESPONSE+0.420
- MYC_TARGETS_V1+0.390
- IL6_JAK_STAT3_SIGNALING+0.380
- PI3K_AKT_MTOR_SIGNALING+0.360
- ANGIOGENESIS+0.350
- INTERFERON_GAMMA_RESPONSE+0.340
Top 10 suppressed
- KRAS_SIGNALING_DN-0.310
- PANCREAS_BETA_CELLS-0.310
- WNT_BETA_CATENIN_SIGNALING-0.260
- SPERMATOGENESIS-0.160
- APICAL_SURFACE-0.020
- HEDGEHOG_SIGNALING-0.010
- P53_PATHWAY+0.060
- MYOGENESIS+0.070
- XENOBIOTIC_METABOLISM+0.070
- BILE_ACID_METABOLISM+0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934921 | — | — | 0.931 |
| 2 | SRR934913 | — | — | 0.925 |
| 3 | 825AC0F8-4D16-4109-AA6A-4648934E3C35 | — | — | 0.916 |
| 4 | 9BFF7746-9003-4941-9590-0B813E00B326 | — | — | 0.916 |
| 5 | 228C2042-804C-47FA-B565-1993E1015D40 | — | — | 0.916 |
| 6 | 2DAB6792-F9AF-4565-BDD5-C9802F3132F4 | — | — | 0.915 |
| 7 | 6CAD21AA-CB33-402E-B64C-685F576B7653 | — | — | 0.914 |
| 8 | 0E5EDC5A-5AD4-499E-8777-CA6B6F63307F | — | — | 0.913 |
| 9 | AA762299-102B-4E35-B4A5-A94A122EF9DB | — | — | 0.912 |
| 10 | SRR934897 | — | — | 0.911 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 44 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.530 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.530 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.520 | Inavolisib | — uncovered |
| APOPTOSIS | 0.430 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.420 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.390 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.380 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.360 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.350 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.340 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.340 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.330 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.320 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.320 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.310 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.310 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.300 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.280 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.270 | Temsirolimus | — uncovered |
| UV_RESPONSE_DN | 0.270 | Inavolisib | — uncovered |